Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weissleder, R.
Right arrow Articles by Brady, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weissleder, R.
Right arrow Articles by Brady, T. J.

Radiology, Vol 181, 245-249, Copyright © 1991 by Radiological Society of North America

ARTICLES

Polyclonal human immunoglobulin G labeled with polymeric iron oxide: antibody MR imaging

R Weissleder, AS Lee, AJ Fischman, P Reimer, T Shen, R Wilkinson, RJ Callahan and TJ Brady
Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown 02129.

Human polyclonal immunoglobulin (Ig) G was attached to a monocrystalline iron oxide nanocompound (MION), a small superparamagnetic probe developed for receptor and antibody magnetic resonance (MR) imaging. The resulting complex, MION-IgG, had a slightly negative surface charge, a molecular weight of 150-180 kDa, and 0.36 microgram of IgG attached per milligram of iron. After intravenous administration of MION-IgG to normal rats, most of the compound localized in liver, spleen, and bone marrow. In an animal model of myositis, MION-IgG caused reduced signal intensity (most apparent on T2- weighted spin-echo and gradient-echo images) at the site of inflammation. No change in signal intensity existed after an injection of unlabeled MION. Site-specific localization of MION-IgG was corroborated with scintigraphic imaging with indium-111 IgG and MION-In- 111-IgG and was confirmed histologically with iron staining. These results indicate that antibody MR imaging is feasible in vivo. Target- specific and antibody MR imaging could be easily extended to other applications, including detection of cancer, infarction, and degenerative diseases.


This article has been cited by other articles:


Home page
 CirculationHome page
D. E. Sosnovik, M. Nahrendorf, and R. Weissleder
Molecular Magnetic Resonance Imaging in Cardiovascular Medicine
Circulation, April 17, 2007; 115(15): 2076 - 2086.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. G. Blasberg
Molecular Imaging and Cancer
Mol. Cancer Ther., March 1, 2003; 2(3): 335 - 343.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Moore, S. Bonner-Weir, and R. Weissleder
Noninvasive In Vivo Measurement of {beta}-Cell Mass in Mouse Model of Diabetes
Diabetes, October 1, 2001; 50(10): 2231 - 2236.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1991 by the Radiological Society of North America.